Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.

REGN Regeneron Pharmaceuticals Inc

19.14 (1.86%)
Jun 14 2024 - Closed
Delayed by 15 minutes


Draw Mode:

Volume 353,917
Bid Price 1,036.87
Ask Price 1,046.00
News (2)
Day High 1,042.66


52 Week Range


Day Low 1,028.285
Company Name Stock Ticker Symbol Market Type
Regeneron Pharmaceuticals Inc REGN NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
19.14 1.86% 1,045.69 20:00:00
Open Price Low Price High Price Close Price Prev Close
1,024.30 1,028.285 1,042.66 1,036.52 1,026.55
Trades Volume VWAP Dollar Volume Avg Volume 52 Week Range
16,560 353,917 $ 1,034.70 $ 366,196,964 - 684.805 - 1,042.66
Last Trade Time Type Quantity Stock Price Currency
19:46:16 1 $ 1,044.78 USD

Regeneron Pharmaceuticals (REGN) Options Flow Summary

Overall Flow


Net Premium


Calls / Puts


Buys / Sells




Sweeps Ratio


Regeneron Pharmaceuticals Inc Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
113.77B 109.76M - 13.12B 3.95B 36.02 28.78
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- - - -

more financials information »

Regeneron Pharmaceuticals News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....

No posts yet, be the first! No REGN Message Board. Create One! See More Posts on REGN Message Board See More Message Board Posts

Historical REGN Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week999.001,042.66992.221,015.61343,59346.694.67%
1 Month969.271,042.66952.30992.20383,91376.427.88%
3 Months973.001,042.66875.225949.48427,11372.697.47%
6 Months873.811,042.66838.455936.78495,118171.8819.67%
1 Year766.071,042.66684.805858.08514,634279.6236.50%
3 Years525.621,042.66516.75717.87634,241520.0798.94%
5 Years306.811,042.66271.37596.76761,045738.88240.83%

Regeneron Pharmaceuticals Description

Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases; Praluent for LDL cholesterol lowering; Dupixent in atopic dermatitis, asthma, and nasal polyposis; Libtayo in cutaneous squamous cell carcinoma; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal antibodies with Sanofi in immunology and cancer, and bispecific antibodies and antibody cocktails with other collaborators and independently.

Your Recent History

Delayed Upgrade Clock